Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/22/2019 |
Start Date: | February 2014 |
Contact: | Judy Boughey, MD |
Phone: | 507-284-3629 |
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
This randomized phase III trial studies axillary lymph node dissection to see how well it
works compared to axillary radiation therapy in treating patients with node-positive breast
cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may
remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate
whether radiation therapy is as effective as lymph node dissection.
works compared to axillary radiation therapy in treating patients with node-positive breast
cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may
remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate
whether radiation therapy is as effective as lymph node dissection.
Study Outline:
- All patients will undergo surgery to identify sentinel lymph node(s). If a lymph node
(sentinel or non-sentinel) is determined to be positive on intra-operative pathology the
patient will be registered/randomized intra-operatively.
- Patients who do not have a sentinel lymph node identified will not be
registered/randomized to the study.
- Patients whose sentinel lymph node status is cannot be/is not determined intra-
operatively, and have not undergone ALND, but had at least one lymph node (sentinel or
non-sentinel) found to be positive on final pathology review will be
registered/randomized post-operatively.
- Patients whose sentinel lymph node status is found to be negative intra-operatively and
have not undergone ALND, but had at least one lymph node (sentinel or non-sentinel)
found to be positive on final pathology review will be registered/randomized
post-operatively.
- ALND is not to be performed prior to registration/randomization.
- Patients who are determined to have negative lymph nodes on final pathology will not be
registered/randomized, but can be offered participation in another cooperative group
trial.
The primary and secondary objectives of the study are described below. Please see the "Arms"
section for a detailed description of the treatment regimens.
Primary Objective:
- To evaluate whether radiation to the undissected axilla and regional lymph nodes is not
inferior to axillary lymph node dissection with radiation to the regional lymph nodes
but not to the dissected axilla in terms of invasive breast cancer recurrence-free
interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
Secondary Objectives:
- To evaluate whether radiation to the undissected axilla and regional lymph nodes is not
inferior to axillary lymph node dissection with radiation to the regional lymph nodes
but not to the dissected axilla in terms of the incidence of invasive loco-regional
recurrences in patients with a positive SLN(s) after completion of neoadjuvant
chemotherapy
- To obtain an estimate of the distribution of residual disease burden scores for each
treatment arm
- To estimate the distribution of overall survival for each treatment arm
Patients may receive adjuvant and ancillary therapy as appropriate per the protocol.
Adjuvant Therapy:
- Adjuvant endocrine therapy: Patients with hormone receptor (ER and/or PR) positive
disease should receive a minimum of 5 years of standard endocrine therapy (experimental
agents/regimens are not permitted). Endocrine therapy should begin following completion
of neoadjuvant chemotherapy and surgery, either before, during or after radiation
therapy at the discretion of the oncologist. Selection of the agents is at the treating
physician's discretion.
- Patients with HER 2 positive disease should complete a total of one year of trastuzumab
therapy (over the neoadjuvant and adjuvant period).
- Chemotherapy, biologic therapy or vaccine therapy in the adjuvant setting is not
allowed.
Patients who wish to receive any of these therapies after surgery must go off study at the
time of their initiation.
Ancillary Therapy:
- Patients should receive full supportive care, including transfusions of blood and blood
products, erythropoetin (unless otherwise specified in the protocol), antibiotics,
antiemetics, etc. when appropriate.
Patients are followed up for 5 years after completion of radiation therapy.
- All patients will undergo surgery to identify sentinel lymph node(s). If a lymph node
(sentinel or non-sentinel) is determined to be positive on intra-operative pathology the
patient will be registered/randomized intra-operatively.
- Patients who do not have a sentinel lymph node identified will not be
registered/randomized to the study.
- Patients whose sentinel lymph node status is cannot be/is not determined intra-
operatively, and have not undergone ALND, but had at least one lymph node (sentinel or
non-sentinel) found to be positive on final pathology review will be
registered/randomized post-operatively.
- Patients whose sentinel lymph node status is found to be negative intra-operatively and
have not undergone ALND, but had at least one lymph node (sentinel or non-sentinel)
found to be positive on final pathology review will be registered/randomized
post-operatively.
- ALND is not to be performed prior to registration/randomization.
- Patients who are determined to have negative lymph nodes on final pathology will not be
registered/randomized, but can be offered participation in another cooperative group
trial.
The primary and secondary objectives of the study are described below. Please see the "Arms"
section for a detailed description of the treatment regimens.
Primary Objective:
- To evaluate whether radiation to the undissected axilla and regional lymph nodes is not
inferior to axillary lymph node dissection with radiation to the regional lymph nodes
but not to the dissected axilla in terms of invasive breast cancer recurrence-free
interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
Secondary Objectives:
- To evaluate whether radiation to the undissected axilla and regional lymph nodes is not
inferior to axillary lymph node dissection with radiation to the regional lymph nodes
but not to the dissected axilla in terms of the incidence of invasive loco-regional
recurrences in patients with a positive SLN(s) after completion of neoadjuvant
chemotherapy
- To obtain an estimate of the distribution of residual disease burden scores for each
treatment arm
- To estimate the distribution of overall survival for each treatment arm
Patients may receive adjuvant and ancillary therapy as appropriate per the protocol.
Adjuvant Therapy:
- Adjuvant endocrine therapy: Patients with hormone receptor (ER and/or PR) positive
disease should receive a minimum of 5 years of standard endocrine therapy (experimental
agents/regimens are not permitted). Endocrine therapy should begin following completion
of neoadjuvant chemotherapy and surgery, either before, during or after radiation
therapy at the discretion of the oncologist. Selection of the agents is at the treating
physician's discretion.
- Patients with HER 2 positive disease should complete a total of one year of trastuzumab
therapy (over the neoadjuvant and adjuvant period).
- Chemotherapy, biologic therapy or vaccine therapy in the adjuvant setting is not
allowed.
Patients who wish to receive any of these therapies after surgery must go off study at the
time of their initiation.
Ancillary Therapy:
- Patients should receive full supportive care, including transfusions of blood and blood
products, erythropoetin (unless otherwise specified in the protocol), antibiotics,
antiemetics, etc. when appropriate.
Patients are followed up for 5 years after completion of radiation therapy.
Pre-Registration Eligibility Criteria:
1. Patients ≥ 18 years of age
2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of
neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th
edition
3. No inflammatory breast cancer
4. No other malignancy within 5 years of registration with the exception of basal cell or
squamous cell carcinoma of the skin treated with local resection only or carcinoma in
situ of the cervix
5. All patients must have had an axillary ultrasound with fine needle aspiration (FNA) or
core needle biopsy of axillary lymph nodes documenting axillary metastasis at the time
of diagnosis, prior to or at most 14 days after starting neoadjuvant chemotherapy.
Note: Biopsy of intramammary nodes does not fulfill eligibility criteria.
6. Patients must have had estrogen receptor, progesterone receptor and human epidermal
growth factor receptor 2 (HER2) status by immunohistochemistry [IHC] and/or
fluorescence in situ hybridization [FISH] evaluated on diagnostic core biopsy prior to
start of neoadjuvant chemotherapy. Note: If HER2 status has not been clearly
determined (ie equivocal/indeterminate), then patients should not be enrolled.
7. Patients must have completed all planned chemotherapy prior to surgery. Sandwich
chemotherapy is not allowed (i.e. chemotherapy planned to be given after surgery).
Patients must have completed at least 4 cycles of neoadjuvant chemotherapy consisting
of an anthracycline and/or taxane-based regimen without evidence of disease
progression in the breast or the lymph nodes. NOTE: Delays/dose modifications due to
toxicities/adverse events are allowed as long as a minimum of 4 cycles of neoadjuvant
chemotherapy is administered. More than 4 cycles of NAC may be administered at the
discretion of the treating medical oncologist.
8. Patients with HER-2 positive tumors must have received neoadjuvant trastuzumab or
trastuzumab + pertuzumab or other approved anti-HER-2 therapy (either with all or with
a portion of the neoadjuvant chemotherapy regimen). Therapy must be Food and Drug
Administration (FDA)-approved targeted anti-HER2 therapy, but additional therapies are
allowed as are non-trastuzumab regimens if administered in the context of an
Institutional Review Board (IRB)-approved clinical trial.
9. All patients must have a clinically negative axilla (no palpable lymph nodes or bulky
adenopathy) on physical examination documented at the completion of neoadjuvant
chemotherapy. NOTE: An ultrasound of the axilla is not required at completion of
neoadjuvant chemotherapy. If performed, its findings do NOT impact eligibility.
10. No neoadjuvant endocrine therapy
11. No neoadjuvant radiation therapy
12. No sentinel lymph node (SLN) surgery/excisional biopsy for pathological confirmation
of axillary status prior to or during neoadjuvant chemotherapy
13. No prior history of ipsilateral breast cancer (invasive disease or ductal carcinoma in
situ [DCIS]). Lobular carcinoma in situ (LCIS) and benign breast disease is allowed.
14. No prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or
treatment of hidradenitis.
15. No history of prior or concurrent contralateral invasive breast cancer. Benign breast
disease, LCIS or DCIS of contralateral breast is allowed.
16. Patients must not be pregnant or nursing. A negative pregnancy test is required prior
to registration for women of childbearing potential. Note: Peri-menopausal women must
be amenorrheic for > 12 months to be considered not of childbearing potential.
17. Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1.
18. Required Pre-Registration Laboratory Values:
- Serum or urine beta-human chorionic gonadotropin (ß-HCG)
- Negative in women of child-bearing potential
Intra-Operative Registration/Randomization Criteria:
1. Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be
completed within 56 days of the completion of neoadjuvant chemotherapy.
2. A minimum of 1 sentinel node and a maximum of 6 total nodes (sentinel + non-sentinel)
are identified and excised by the surgeon. Patients who do not have an identifiable
sentinel lymph node will not proceed to Registration/Randomization.
3. At least one lymph node (sentinel or non-sentinel) with a metastasis greater than 0.2
mm in greatest dimension identified on intra-operative pathologic assessment. Note:
Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as node
negative disease (N0i+). Axillary lymph node dissection [ALND] is not to be performed
prior to Registration/Randomization.
Post-Operative Registration/Randomization Criteria:
1. For cases where ALND has not been performed and one of the following is true:
- intra-operative evaluation of sentinel lymph node could not be/was not performed and
final pathology identified a positive lymph node (sentinel or non-sentinel) with
metastasis greater than 0.2 mm on hematoxylin and eosin stain (H & E) OR
- lymph node (sentinel or non-sentinel) considered negative on intra-operative
evaluation was found to be positive on final pathology (with metastasis greater than
0.2 mm on H & E)
- Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be
completed within 56 days of the completion of neoadjuvant chemotherapy.
- At least one lymph node (sentinel or non-sentinel) with a metastasis greater than
0.2 mm in greatest dimension identified by H&E staining on final pathology (for
cases where intra-operative evaluation was not performed, or was negative and
completion dissection was not performed).
- Among the minimum of 1 and the maximum of 6 nodes (sentinel or non-sentinel)
identified and excised by the surgeon, no more than 8 lymph nodes (sentinel and
non-sentinel) were found by the pathologists to have been actually excised. Note:
Isolated tumor cells (metastases less than or equal to 0.2 mm) will be treated as
node negative disease (N0i+).
- For those patients who also undergo contralateral breast surgery, if invasive
disease is found in the contralateral breast, the patient is not eligible for
registration/randomization.
We found this trial at
1138
sites
Roseville, California 95661
Principal Investigator: Edmund W. Tai
Phone: 415-209-2686
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Stephanie G. Fine
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
8600 Old Georgetown Road
Bethesda, Maryland 20814
Bethesda, Maryland 20814
301-896-3100
Principal Investigator: Lisa K. Jacobs
Phone: 301-896-2719
Suburban Hospital Suburban Hospital is a community-based, not-for-profit hospital serving Montgomery County and the surrounding...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Laura S. Dominici
Phone: 773-702-9171
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Michelle Sowden
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Shayna L. Showalter
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
Dallas, Texas 75246
1.800.422.9567
Principal Investigator: Jeffrey P. Lamont
Phone: 800-422-9567
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Lisa D. Yee
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Costanza Cocilovo
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: V. S. Klimberg
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Ronda S. Henry-Tillman
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Armando E. Giuliano
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Arpana M. Naik
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
620 John Paul Jones Cir
Portsmouth, Virginia 23708
Portsmouth, Virginia 23708
(757) 953-5008
Principal Investigator: Andrew S. Camarata
Phone: 757-953-5939
Naval Medical Center - Portsmouth Naval Medical Center Portsmouth, Virginia has proudly served the military...
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Kara L. Leonard
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Harry D. Bear
Phone: 773-702-9171
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
34800 Bob Wilson Dr,
San Diego, California 92134
San Diego, California 92134
(619) 532-6400
Principal Investigator: Harvey B. Wilds
Phone: 619-532-8712
Naval Medical Center - San Diego We are the largest and most comprehensive military healthcare...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Janice N. Kim
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Janice N. Kim
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 509-574-3535
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Click here to add this to my saved trials
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Stephanie G. Fine
Phone: 773-702-9171
Click here to add this to my saved trials
Alexandria, Virginia 22304
Principal Investigator: Costanza Cocilovo
Phone: 703-776-2580
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
Principal Investigator: Carlos A. Alemany
Phone: 773-702-9171
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Daniel Arsenault
Phone: 806-212-1985
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Annapolis, Maryland 21401
Principal Investigator: Mary E. Young
Phone: 443-481-1320
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Honnie R. Bermas
Phone: 800-574-3872
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Honnie R. Bermas
Phone: 920-380-1500
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Honnie R. Bermas
Phone: 844-510-3600
Click here to add this to my saved trials
1506 South Oneida Street
Appleton, Wisconsin 54915
Appleton, Wisconsin 54915
Principal Investigator: Robert R. Kohl
Phone: 920-831-8900
Click here to add this to my saved trials
Arlington, Texas 76014
Principal Investigator: Vivek S. Kavadi
Phone: 817-467-6092
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0836
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Kellie S. Condra
Phone: 800-506-2550
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Kellie S. Condra
Phone: 828-213-4150
Click here to add this to my saved trials
Asheville, North Carolina 28816
Principal Investigator: Kellie S. Condra
Phone: 773-702-9171
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-353-5006
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Preeti D. Subhedar
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
Atlanta, Georgia 30309
(404) 605-5000
Principal Investigator: Adam W. Nowlan
Phone: 404-425-7943
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
Click here to add this to my saved trials
Atlanta, Georgia 30303
Principal Investigator: Preeti D. Subhedar
Phone: 404-489-9164
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Preeti D. Subhedar
Phone: 404-778-1868
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Preeti D. Subhedar
Phone: 888-823-5923
Click here to add this to my saved trials
Atlantis, Florida 33462
Principal Investigator: Georges F. Hatoum
Phone: 561-964-2662
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Edmund W. Tai
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Nicole Kounalakis
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Click here to add this to my saved trials
Avon, Indiana 46123
Principal Investigator: Lisa R. Korff
Phone: 317-278-5632
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 206-342-6954
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Richard J. Bold
Phone: 661-323-4673
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Madhu Chaudhry
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Baltimore, Maryland 21218
Principal Investigator: Shawna C. Willey
Phone: 410-261-8151
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Elizabeth M. Nichols
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Dona C. Hobart
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
Baltimore, Maryland 21229
Principal Investigator: Richard S. Hudes
Phone: 410-368-2910
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Shawna C. Willey
Phone: 443-777-7364
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Lisa K. Jacobs
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
Baltimore, Maryland 21239
Principal Investigator: Shawna C. Willey
Phone: 410-261-8151
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials